ISOPP 2025 Dispatch – Day 1: BiTEs, B-ALL, CSTDs & ADCs

ISOPP 2025 Dispatch – Day 4: Lung/GU Cancers, Abstracts, Home Care, Scope Expansion & Breast Cancer Models

Summary This episode wraps up the coverage of the ISOPP CAPhO 2025 symposium, highlighting key sessions from the final day. It covers clinical updates in lung and urothelial cancers, innovative approaches in cancer care, the capacity crisis in cancer services, the expanding roles of pharmacists and technicians, and innovative models of care in breast cancer. The discussion emphasizes the importance of proactive management, patient-centered care, and the integration of technology in oncology pharmacy practice.

ISOPP 2025 Dispatch – Day 3: EDI, PGx, CAT, AI & BIG NEWS!!!

Eoin Tabb reports from Day 3 of the ISOPP CAPhO 2025 Symposium in Victoria, Canada. This episode delves into crucial discussions on Equity, Diversity, and Inclusion (EDI) in pharmacy practice, the benefits and risks of Artificial Intelligence (AI) in oncology, updates on preventing Cancer-Associated Thrombosis (CAT), and the implementation of pre-therapeutic Pharmacogenomics (PGx), including combining DPYD testing with Therapeutic Drug Monitoring (TDM) for 5-FU. Plus, hear exciting news from the ISOPP AGM about next year's unique 24-hour virtual conference format and a special collaboration with the Irish Pharmacy Haematology Oncology Society (IPHOS)! #ISOPPCAPhO2025 #OncologyPharmacy #Haematology #ClinicalPharmacy #EDI #AI #PGx #TDM #CAT CAT Survey: https://redcap.alfredhealth.org.au/redcap/surveys/index.php?s=dFo7DpNgVBauTYeW&__startover=1 [https://redcap.alfredhealth.org.au/redcap/surveys/index.php?s=dFo7DpNgVBauTYeW&__startover=1]

ISOPP 2025 Dispatch – Day 2: PARPis, Culture, Standards, Disasters, Sustainability, Efficiency, Infections, Geriatrics & Safety

Join Eoin Tabb for the second daily dispatch from the ISOPP CAPhO 2025 Symposium in Victoria, Canada. Day 2 covered a wide spectrum of crucial topics for haematology/oncology pharmacy practice. Highlights include practical management strategies for PARP inhibitors, the importance of cultural humility and discussing traditional medicines, ISOPP's new global service level framework, pharmacy's role in disaster preparedness and environmental sustainability, efficiencies in myeloma treatment administration (pre-meds, infusion times, schedules), managing CMV infections, considerations for treating older/unfit patients using geriatric assessment, and critical updates on hazardous drug lists and safety. Tune in for key insights and takeaways relevant to Irish practice! #ISOPPCAPhO2025 #OncologyPharmacy #Haematology #ClinicalPharmacy PARPi Clinical Resource: https://cdn.ymaws.com/www.cano-acio.ca/resource/resmgr/endorsements/en_parp_inhibitor_clinical_r.pdf [https://cdn.ymaws.com/www.cano-acio.ca/resource/resmgr/endorsements/en_parp_inhibitor_clinical_r.pdf]

ISOPP 2025 Dispatch – Day 1: BiTEs, B-ALL, CSTDs & ADCs

Join host Eoin Tabb for a special dispatch episode recorded live from the ISOPP 2025 Symposium in Victoria, BC. Get your 'audio delegate bag' with key insights from Day 1, covering:   * Implementing bispecific antibodies (BiTEs) like teclistamab and talquetamab in multiple myeloma, focusing on community administration and managing toxicities (CRS, ICANS, infections, oral/skin/nail issues).   * The practice-changing impact of blinatumomab in frontline B-ALL based on the E1910 trial.   * Innovations in hazardous drug safety using Closed System Transfer Devices (CSTDs) and automation.   * SMART strategies for managing toxicities (ILD, neutropenia, nausea, neuropathy) of ADCs like T-DXd, T-DM1, and Sacituzumab Govitecan in metastatic breast cancer.

Safe Prescribing in Systemic Anticancer Treatments

Podcast Description: Navigating the complexities of systemic anticancer therapy (SACT) demands meticulous attention to detail, especially when it comes to prescribing. In this episode of the Irish Haematology Oncology Podcast, join your host Eoin Tabb as he delves into the critical aspects of safe prescribing practices for SACT. We'll explore the reasons why SACT prescribing is considered high-risk, the essential steps involved in the prescribing process for both first and subsequent cycles, and the key components of a comprehensive treatment plan. We'll also discuss the legal requirements and prescribing standards, strategies to mitigate errors, and the unique safety challenges associated with oral anticancer medicines (OAMs). Whether you're at the beginning of your career or seeking a refresher, this episode will equip you with the knowledge and insights to ensure the safe and effective administration of these powerful medications to your patients. Takeaways * DPYD testing is crucial for personalized cancer treatment. * SACT medications have a narrow therapeutic index. * Creating a treatment plan requires meaningful patient conversations. * Clear communication among healthcare professionals is essential. * Legal standards in prescribing protect patients and prescribers. * Ambiguity in prescriptions can lead to serious errors. * Pharmacists play a critical role in patient safety. * Oral anti-cancer medicines come with unique safety challenges. * Regular reassessment of patient fitness for treatment is necessary. * Safe prescribing is a shared responsibility among all healthcare providers. Feedback Form [https://docs.google.com/forms/d/e/1FAIpQLSfmnWa8X5fJVn99TSZr9qw30sD9XRvelLeU8BFzDXS1YqIX1A/viewform?usp=sharing] IIOP Example CPD for Pharmacists [https://docs.google.com/document/d/1FjokvM1Mt7biwfPVFipWMyMJo4BZr_q_Fgl8M9dSPv0/edit?usp=sharing]